CRISPR筛选揭示ALK阳性间变性大细胞淋巴瘤PD-L1调控新模型
研究利用CRISPR/Cas9文库筛选,在ALK阳性间变性大细胞淋巴瘤中鉴定PD-L1表达依赖NPM-ALK通过STAT3及含GRB2/SOS1信号体激活MEK-ERK和PI3K-AKT通路,最终由IRF4和BATF3作用于PD-L1基因增强子区诱导表达;靶向该通路可抑制PD-L1介导的免疫逃逸。
要点
- CRISPR/Cas9筛选揭示ALK+ ALCL中PD-L1诱导依赖NPM-ALK-STAT3及GRB2/SOS1信号体。
- IRF4和BATF3作用于PD-L1基因增强子区,是PD-L1上调所必需。
- 靶向该致癌信号通路可抑制与PD-1阳性T细胞和NK细胞共培养时的PD-L1介导免疫逃逸。
核心结论
- ALK+ ALCL中PD-L1诱导依赖NPM-ALK激活STAT3及含GRB2/SOS1信号体,经IRF4和BATF3作用于PD-L1增强子实现。
- 靶向该通路可抑制PD-L1介导的肿瘤免疫逃逸。
研究设计与样本
- 研究采用CRISPR/Cas9文库筛选,在ALK+ ALCL中系统鉴定PD-L1调控的分子效应器。
- 研究纳入原发ALK+ ALCL组织分析IRF4与PD-L1表达相关性。
主要发现
- PD-L1诱导依赖NPM-ALK癌蛋白激活STAT3及含GRB2/SOS1信号体,后者激活MEK-ERK和PI3K-AKT通路。
- STAT3和GRB2/SOS1信号网络通过转录因子IRF4和BATF3作用于PD-L1基因增强子区诱导PD-L1表达。
- IRF4和BATF3对PD-L1上调必不可少,原发ALK+ ALCL组织中IRF4表达与PD-L1水平相关。
- 靶向该致癌信号通路在与PD-1阳性T细胞和自然杀伤细胞共培养时大幅抑制PD-L1介导的肿瘤免疫逃逸。
临床怎么用
- 该调控枢纽为改进免疫治疗干预策略提供了新机会。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The success of programmed cell death protein 1 (PD-1)/PD-L1-based immunotherapy highlights the critical role played by PD-L1 in cancer progression and reveals an urgent need to develop new approaches to attenuate PD-L1 function by gaining insight into how its expression is controlled. Anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALK+ ALCL) expresses a high level of PD-L1 as a result of the constitutive activation of multiple oncogenic signaling pathways downstream of ALK activity, making it an excellent model in which to define the signaling processes responsible for PD-L1 upregulation in tumor cells. Here, using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 library screening, we sought a comprehensive understanding of the molecular effectors required for PD-L1 regulation in ALK+ ALCL. Indeed, we determined that PD-L1 induction is dependent on the nucleophosmin-ALK oncoprotein activation of STAT3, as well as a signalosome containing GRB2/SOS1, which activates the MEK-ERK and PI3K-AKT signaling pathways. These signaling networks, through STAT3 and the GRB2/SOS1, ultimately induce PD-L1 expression through the action of transcription factors IRF4 and BATF3 on the enhancer region of the PD-L1 gene. IRF4 and BATF3 are essential for PD-L1 upregulation, and IRF4 expression is correlated with PD-L1 levels in primary ALK+ ALCL tissues. Targeting this oncogenic signaling pathway in ALK+ ALCL largely inhibited the ability of PD-L1-mediated tumor immune escape when cocultured with PD-1-positive T cells and natural killer cells. Thus, our identification of this previously unrecognized regulatory hub not only accelerates our understanding of the molecular circuitry that drives tumor immune escape but also provides novel opportunities to improve immunotherapeutic intervention strategies.
引用
- Zhang JP, Song Z, Wang HB, et al. A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening. Blood. 2019. PMID: 31151983. doi:10.1182/blood.2019001043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。